-
Moderna's stock price jumped early Thursday as the biotech firm drew one step closer to revealing how well its experimental coronavirus vaccine works.
-
The announcement Sunday at the end of the day of a vaccine candidate '90% effective' is a shock. This announcement also raises many questions. Here are five, to help you see more clearly.
-
In the global race for vaccines against the coronavirus, ten projects have reached phase III of clinical trials, the last stage before obtaining or not obtaining validation from the health authorities, but what are the criteria likely to tip the balance?
-
US stocks were set for a mixed opening Tuesday after Pfizer’s coronavirus vaccine breakthrough led investors to reshuffle their portfolios.
Futures contracts tied to the Dow Jones industrial
-
Nearly 200 vaccine candidates against the coronavirus are being studied around the world. 198, precisely, counted the World Health Organization, ten of which entered the third phase of testing, the one before marketing. This Monday, Pfizer hit the headlines by announcing convincing results, but where are the others?
-
Pfizer will likely have millions of coronavirus vaccine doses ready by the end of 2020 — and the company’s CEO is willing to be one of the first to take it.
The Manhattan-based drugmaker
-
The US Food and Drug Administration has granted “fast track” status to Novavax’s experimental coronavirus vaccine, the company announced Monday.
The designation will allow the
-
President-elect Joe Biden's health care advisers met with drug companies before last week's election about their efforts to produce coronavirus vaccines and treatments, a new report says.
-
US stocks marched to all-time highs Monday as Wall Street hailed a major milestone in the race for a coronavirus vaccine.
The Dow Jones industrial average surged as much as 1,610.4 points, or about
-
Shares of companies that have benefited from the pandemic -- including Zoom, Peloton, Netflix and Amazon --tanked after Pfizer revealed that it is getting closer to a coronavirus vaccine.
Moderna's stock price jumped early Thursday as the biotech firm drew one step closer to revealing how well its experimental coronavirus vaccine works.
